Assessment of Tolerance of Mobilizing Peripheral Hematopoietic Stem Cells by Plerixafor in Sickle Cell Patients

NCT02212535 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

3

Enrollment

OTHER

Sponsor class

Conditions

Major Sickle Cell Syndrome of Type SS or Sβ Thalassemia

Interventions

DRUG: Plerixafor

Sponsor

Assistance Publique - Hôpitaux de Paris

Collaborators

[object Object]